Biofrontera Inc.: quarterly results

BFRINASDAQHealthcare · Pharmaceutical Preparations

Price

$0.63

November 16, 2026Market cap $11M

What Ploutos Investor adds for Biofrontera

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 44% since Aug 13, 2026, when the 10-Q these figures come from was filed ($1.26 then, $0.70 on Nov 13, 2026). The figures date from before that move.10-Q

Results, quarter by quarter

When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.

Nov 13, 2026 last results

Next results

in 88 daysAround Feb 12, 2027 · for Q4 2026

last Nov 13, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

The first session after results

±7.4%average move, either way

2 times upof the last 42 times down

Largest: -24.4% on Nov 13, 2026 (Q3 2026).

How the stock moved after each release

The close of the first session after the results against the close before them.

BFRI that sessionS&P 500 the same day

Every release

Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.

  • Q3 2026
    Stock, next session-24.4%
  • Q2 2026
    Stock, next session+0.8%
  • Q1 2026
    Stock, next session+3.0%
  • Q4 2025
    Stock, next session-1.5%

Every release

BFRI's results days and the share's move after each, from Q3 2021 to Q4 2025, 26 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 8 quarters.

Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one.

The full analysis

What do Biofrontera's filings show?

The results say what Biofrontera reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.